

Product Data Sheet

Minodronic acid

 Cat. No.:
 HY-16322

 CAS No.:
 180064-38-4

 Molecular Formula:
 C₉H₁₂N₂O₇P₂

 Molecular Weight:
 322.15

Target: P2X Receptor; Apoptosis

Pathway: Membrane Transporter/Ion Channel; Apoptosis

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year

SOLVENT & SOLUBILITY

In Vitro H₂O: 5 mg/mL (15.52 mM; Need ultrasonic and warming)

DMSO: < 1 mg/mL (insoluble or slightly soluble)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.1041 mL	15.5207 mL	31.0414 mL
	5 mM	0.6208 mL	3.1041 mL	6.2083 mL
	10 mM	0.3104 mL	1.5521 mL	3.1041 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo 1. Add each solvent one by one: PBS

Solubility: 2 mg/mL (6.21 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces

apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic

P2X2/3 receptors involved in pain^{[1][2]}.

IC₅₀ & Target P2X2/3^[2]

REFERENCES

[1]. Sato K, et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer. 2006 Nov 20;95(10):1354-61.

2]. Tanaka M, et al. Minodronic 2XX2/3 receptors. J Bone Miner			esorption sites and reaches a level re	equired for antagonism of purinergic
	Caution: Product has not	t been fully validated for me	dical applications. For research (use only.
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpr	ress.com
	Address: 1 D	eer Park Dr, Suite Q, Monmo	uth Junction, NJ 08852, USA	

Page 2 of 2 www.MedChemExpress.com